Duloxetine Capsule, Delayed Release
Product Images NDC 70518-1139

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-1139). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine 20mg 70518 1139 00

The label for Duloxetine 20 mg delayed-release capsules shows a quantity of 30 capsules. It is labeled for prescription use only (RX ONLY) with NDC 70518-1139-00. The label includes the manufacturer Ajanta Pharma Ltd. in India and repackager RemedyRepack Inc., Indiana. It advises to keep medication out of children's reach and references storage conditions and directions in the package insert.*

FDA Label Image

Duloxetine Fig1

A Kaplan-Meier plot depicting the proportion of patients with relapse over time from randomization to relapse (days). The graph compares two treatment groups: Placebo and Duloxetine, showing respective relapse proportions on the y-axis and days on the x-axis, up to approximately 200 days.*

FDA Label Image

Duloxetine Fig10

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The plot shows two lines: one for placebo and one for Duloxetine 60/120 mg once daily. The Duloxetine line consistently trends above the placebo line, indicating higher patient improvement percentages across various pain improvement thresholds.*

FDA Label Image

Duloxetine Fig2

A line graph comparing the proportion of patients with relapse over time (days) from randomization between two treatments: Duloxetine and Placebo. The x-axis represents time in days up to 300, and the y-axis shows proportion of patients with relapse from 0.0 to 1.0. The graph shows two lines, a dashed line for Placebo and a solid line for Duloxetine, illustrating the relapse rates for each treatment over time.*

FDA Label Image

Duloxetine Fig3

A line graph showing the percentage of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The graph compares four groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and Placebo. Each group's trend line shows the relationship between pain improvement percentage and the proportion of patients experiencing improvement.*

FDA Label Image

Duloxetine Fig4

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It shows three treatment groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. Both Duloxetine groups have higher percentages of patients improved across most levels of pain improvement compared to placebo.*

FDA Label Image

Duloxetine Fig5

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph includes three lines representing Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The chart visualizes patient response rates to different Duloxetine dosing regimens compared to placebo across varying levels of pain improvement.*

FDA Label Image

Duloxetine Fig6

A line chart comparing the percentage of patients improved against percent improvement in pain from baseline for three dosages of duloxetine (120 mg, 60 mg, 20 mg once daily) and placebo. The vertical axis shows the percentage of patients improved, and the horizontal axis shows percent improvement in pain from baseline ranging from greater than 0 to 100 percent.*

FDA Label Image

Duloxetine Fig8

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The graph shows higher percentages of patient improvement for Duloxetine across various pain improvement thresholds compared to placebo.*

FDA Label Image

Duloxetine Fig9

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%. Data points for both placebo and Duloxetine are plotted, with Duloxetine showing higher percentages of patient improvement overall.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure diagram of duloxetine hydrochloride, showing its molecular arrangement with a naphthalene group, a thiophene ring, and an amine hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.